Chidozie Ugwumba Sells 3,350 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,350 shares of the firm’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $6.32, for a total value of $21,172.00. Following the transaction, the insider directly owned 795,824 shares of the company’s stock, valued at $5,029,607.68. This represents a 0.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The stock was sold at an average price of $6.54, for a total transaction of $28,560.18.
• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total transaction of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The stock was sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total transaction of $74,276.67.

Clene Stock Up 1.2%

CLNN stock traded up $0.07 during trading on Tuesday, hitting $5.96. The company had a trading volume of 52,752 shares, compared to its average volume of 311,304. The firm has a market capitalization of $61.57 million, a P/E ratio of -1.76 and a beta of 0.79. The company has a 50 day simple moving average of $8.20 and a 200-day simple moving average of $6.34. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50.

Clene (NASDAQ:CLNN) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Sell-side analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CLNN shares. UBS Group reaffirmed a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. D. Boral Capital restated a “buy” rating and set a $23.00 target price on shares of Clene in a research note on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Finally, Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Clene currently has an average rating of “Moderate Buy” and an average target price of $32.60.

Institutional Investors Weigh In On Clene

A number of institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp acquired a new position in Clene in the 3rd quarter worth about $29,000. Jane Street Group LLC acquired a new position in shares of Clene during the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. lifted its position in shares of Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after buying an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP grew its stake in Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).